766 related articles for article (PubMed ID: 24219814)
21. Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosis.
Uttley L; Harnan S; Cantrell A; Taylor C; Walshaw M; Brownlee K; Tappenden P
Eur Respir Rev; 2013 Dec; 22(130):476-86. PubMed ID: 24293463
[TBL] [Abstract][Full Text] [Related]
22. Higher tobramycin concentration and vibrating mesh technology can shorten antibiotic treatment time in cystic fibrosis.
Coates AL; Denk O; Leung K; Ribeiro N; Chan J; Green M; Martin S; Charron M; Edwardes M; Keller M
Pediatr Pulmonol; 2011 Apr; 46(4):401-8. PubMed ID: 21438171
[TBL] [Abstract][Full Text] [Related]
23. Levofloxacin inhalation solution for the treatment of chronic Pseudomonas aeruginosa infection among patients with cystic fibrosis.
Stockmann C; Hillyard B; Ampofo K; Spigarelli MG; Sherwin CM
Expert Rev Respir Med; 2015 Feb; 9(1):13-22. PubMed ID: 25417708
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic and tolerability profiles of tobramycin nebuliser solution 300 mg/4 ml administered by PARI eFlow(®) rapid and PARI LC Plus(®) nebulisers in cystic fibrosis patients.
Govoni M; Poli G; Acerbi D; Santoro D; Cicirello H; Annoni O; Ružička J
Pulm Pharmacol Ther; 2013 Apr; 26(2):249-55. PubMed ID: 23232039
[TBL] [Abstract][Full Text] [Related]
25. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis.
Hodson ME; Gallagher CG; Govan JR
Eur Respir J; 2002 Sep; 20(3):658-64. PubMed ID: 12358344
[TBL] [Abstract][Full Text] [Related]
26. Economic evaluation of Tobramycin nebuliser solution in cystic fibrosis.
Iles R; Legh-Smith J; Drummond M; Prevost A; Vowler S
J Cyst Fibros; 2003 Sep; 2(3):120-8. PubMed ID: 15463860
[TBL] [Abstract][Full Text] [Related]
27. Long-term efficacy and safety of aerosolized tobramycin 300 mg/4 ml in cystic fibrosis.
Mazurek H; Chiron R; Kucerova T; Geidel C; Bolbas K; Chuchalin A; Blanco-Aparicio M; Santoro D; Varoli G; Zibellini M; Cicirello HG; Antipkin YG
Pediatr Pulmonol; 2014 Nov; 49(11):1076-89. PubMed ID: 24464974
[TBL] [Abstract][Full Text] [Related]
28. Clinical pharmacology study of Bramitob, a tobramycin solution for nebulization, in comparison with Tobi.
Poli G; Acerbi D; Pennini R; Soliani Raschini A; Corrado ME; Eichler HG; Eichler I
Paediatr Drugs; 2007; 9 Suppl 1():3-9. PubMed ID: 17536870
[TBL] [Abstract][Full Text] [Related]
29. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.
Sanders DB; Solomon GM; Beckett VV; West NE; Daines CL; Heltshe SL; VanDevanter DR; Spahr JE; Gibson RL; Nick JA; Marshall BC; Flume PA; Goss CH;
J Cyst Fibros; 2017 Sep; 16(5):592-599. PubMed ID: 28460885
[TBL] [Abstract][Full Text] [Related]
30. The use of high resolution computerized tomography (HRCT) of the chest in evaluating the effect of tobramycin solution for inhalation in cystic fibrosis lung disease.
Nasr SZ; Sakmar E; Christodoulou E; Eckhardt BP; Streetman DS; Strouse PJ
Pediatr Pulmonol; 2010 May; 45(5):440-9. PubMed ID: 20425851
[TBL] [Abstract][Full Text] [Related]
31. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis--the TOPIC study: a randomised controlled trial.
Smyth A; Tan KH; Hyman-Taylor P; Mulheran M; Lewis S; Stableforth D; Prof Knox A;
Lancet; 2005 Feb 12-18; 365(9459):573-8. PubMed ID: 15708100
[TBL] [Abstract][Full Text] [Related]
32. Managing Pseudomonas aeruginosa respiratory infections in cystic fibrosis.
Langan KM; Kotsimbos T; Peleg AY
Curr Opin Infect Dis; 2015 Dec; 28(6):547-56. PubMed ID: 26524327
[TBL] [Abstract][Full Text] [Related]
33. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.
Gibson RL; Emerson J; McNamara S; Burns JL; Rosenfeld M; Yunker A; Hamblett N; Accurso F; Dovey M; Hiatt P; Konstan MW; Moss R; Retsch-Bogart G; Wagener J; Waltz D; Wilmott R; Zeitlin PL; Ramsey B;
Am J Respir Crit Care Med; 2003 Mar; 167(6):841-9. PubMed ID: 12480612
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics and safety of an 8 week continuous treatment with once-daily versus twice-daily inhalation of tobramycin in cystic fibrosis patients.
van Koningsbruggen-Rietschel S; Heuer HE; Merkel N; Posselt HG; Staab D; Sieder C; Ziegler J; Krippner F; Rietschel E
J Antimicrob Chemother; 2016 Mar; 71(3):711-7. PubMed ID: 26626719
[TBL] [Abstract][Full Text] [Related]
35. Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.
Ryan G; Jahnke N; Remmington T
Cochrane Database Syst Rev; 2012 Dec; 12():CD008319. PubMed ID: 23235659
[TBL] [Abstract][Full Text] [Related]
36. New clinical evidence from the European tobramycin trial in cystic fibrosis.
Hodson ME; Gallagher CG
J Cyst Fibros; 2002 Dec; 1(Suppl 2):199-202. PubMed ID: 15463835
[TBL] [Abstract][Full Text] [Related]
37. Long-term safety of tobramycin inhalation powder in patients with cystic fibrosis: phase IV (ETOILES) study.
Sommerwerck U; Virella-Lowell I; Angyalosi G; Viegas A; Cao W; Debonnett L
Curr Med Res Opin; 2016 Nov; 32(11):1789-1795. PubMed ID: 27435882
[TBL] [Abstract][Full Text] [Related]
38. Nebulized Colistin And Continuous Cyclic Azithromycin In Severe COPD Patients With Chronic Bronchial Infection Due To
Montón C; Prina E; Pomares X; Cugat JR; Casabella A; Oliva JC; Gallego M; Monsó E
Int J Chron Obstruct Pulmon Dis; 2019; 14():2365-2373. PubMed ID: 31802860
[TBL] [Abstract][Full Text] [Related]
39. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.
Geller DE; Konstan MW; Smith J; Noonberg SB; Conrad C
Pediatr Pulmonol; 2007 Apr; 42(4):307-13. PubMed ID: 17352404
[TBL] [Abstract][Full Text] [Related]
40. An 8 week open-label interventional multicenter study to explore the lung clearance index as endpoint for clinical trials in cystic fibrosis patients ≥8 years of age, chronically infected with Pseudomonas aeruginosa.
Sutharsan S; Naehrig S; Mellies U; Sieder C; Ziegler J
BMC Pulm Med; 2020 Jun; 20(1):167. PubMed ID: 32532226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
